FSTX News and Press, F-star Therapeutics Inc Com From 05/10/22

Four Clinical Readouts Anticipated Throughout 2022 Mechanistic Data on FS118 Demonstrating Shedding Mechanism and LAG-3 Reduction Presented at the 2022 American Association for Cancer Research (AACR) Annual Meeting Company To Host Conference Call Today at 9...

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announced t...

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., April 08, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announced...

F-star Therapeutics Inc. (NASDAQ:FSTX) traded at a new 52-week high today of $15.99. So far today approximately 5.8 million shares have been exchanged, as compared to an average 30-day volume of 133,000 shares. F-star Therapeutics Inc. share prices have moved between a 52-week high of $1...

Summer Infant (SUMR) +29% on Q4 results. Imperial Petroleum (IMPP) +19%. Mullen Automotive (MULN) +19% featured by Yahoo Finance live. Indonesia Energy (INDO) +18%. F-star Therapeutics (FSTX) +16%. Enservco (ENSV) +16%. Aquestive Therapeutics (AQST) +16% receives FDA fast track...

F-star Therapeutics, Inc. (FSTX) Q4 2021 Earnings Conference Call March 14, 2022 9:00 AM ET Company Participants Lindsey Trickett - VP of IR Eliot Forster - CEO Darlene Deptula-Hicks - CFO Conference Call Participants Hartaj Singh - Oppenheimer & Company Daina Graybosch - SVB Leerink Matt...

The following slide deck was published by F-star Therapeutics, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: F-star Therapeutics, Inc. 2022 Q1 - Results - Earnings Call Presentation

F-star Therapeutics press release (NASDAQ:FSTX): FY GAAP EPS of -$1.88 beats by $0.37. Revenue of $21.17M (+88.0% Y/Y) beats by $5.85M. Cash and cash equivalents of $78.5M for the year ended December 31, 2021, compared to $18.5M for the year ended December 31, 2020. For further details see:...

Multiple Clinical Program Updates Expected in 2022 Continued Expansion of Leading Bispecific Antibody IP Estate Two New Significant Partnerships with Janssen and AstraZeneca Company to Host Conference Call Today at 9 a.m. EDT CAMBRIDGE, United Kingdom and C...

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announced...